Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DURHAM, N.C., March 08, 2018 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:40 a.m. ET in Boston, Massachusetts.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.
Contacts
Mark W. Hahn
(919) 338-7936
[email protected]
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
